Literature DB >> 3295686

Processing of the precursor to the major merozoite surface antigens of Plasmodium falciparum.

A A Holder, J S Sandhu, Y Hillman, L S Davey, S C Nicholls, H Cooper, M J Lockyer.   

Abstract

Specific sequences derived from the gene for the precursor to the major merozoite surface antigens (PMMSA) of Plasmodium falciparum have been expressed in Escherichia coli and the products have been used to produce antibodies. These antibodies, together with monoclonal antibodies, have been used to investigate the form of the PMMSA protein associated with merozoites. Polypeptide fragments derived by processing from the PMMSA protein have been detected in extracts of merozoites and assigned to locations within the PMMSA coding sequence.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3295686     DOI: 10.1017/s0031182000053889

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  41 in total

1.  Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria.

Authors:  D Dodoo; T G Theander; J A Kurtzhals; K Koram; E Riley; B D Akanmori; F K Nkrumah; L Hviid
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Oral vaccination of mice against rodent malaria with recombinant Lactococcus lactis expressing MSP-1(19).

Authors:  Zhi-Hong Zhang; Pei-Hong Jiang; Ning-Jun Li; Mi Shi; Weida Huang
Journal:  World J Gastroenterol       Date:  2005-11-28       Impact factor: 5.742

3.  Modification of a human monoclonal antibody Fab fragment specific for Plasmodium falciparum 19-kDa C-terminal merozoite surface protein 1 by site-directed mutagenesis.

Authors:  Yan-Lin Tao; Xun-Jia Cheng; Yong-Feng Fu; Hideo Tsukamoto; Eisaku Yoshihara; Hiroshi Tachibana
Journal:  Parasitol Res       Date:  2008-04-30       Impact factor: 2.289

4.  Immunological cross-reactivity of the C-terminal 42-kilodalton fragment of Plasmodium falciparum merozoite surface protein 1 expressed in baculovirus.

Authors:  G S Hui; C Hashiro; C Nikaido; S E Case; A Hashimoto; H Gibson; P J Barr; S P Chang
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

5.  Global identification of multiple substrates for Plasmodium falciparum SUB1, an essential malarial processing protease.

Authors:  Natalie C Silmon de Monerri; Helen R Flynn; Marta G Campos; Fiona Hackett; Konstantinos Koussis; Chrislaine Withers-Martinez; J Mark Skehel; Michael J Blackman
Journal:  Infect Immun       Date:  2011-01-10       Impact factor: 3.441

6.  Quantification of the relative contribution of major histocompatibility complex (MHC) and non-MHC genes to human immune responses to foreign antigens.

Authors:  A Jepson; W Banya; F Sisay-Joof; M Hassan-King; C Nunes; S Bennett; H Whittle
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

7.  Advances and challenges in malaria vaccine development.

Authors:  Ruobing Wang; Joseph D Smith; Stefan H I Kappe
Journal:  Expert Rev Mol Med       Date:  2009-12-16       Impact factor: 5.600

8.  Cellular and humoral immune responses to well-defined blood stage antigens (major merozoite surface antigen) of Plasmodium falciparum in adults from an Indian zone where malaria is endemic.

Authors:  L Kabilan; V P Sharma; P Kaur; S K Ghosh; R S Yadav; V S Chauhan
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

9.  Regulated maturation of malaria merozoite surface protein-1 is essential for parasite growth.

Authors:  Matthew A Child; Christian Epp; Hermann Bujard; Michael J Blackman
Journal:  Mol Microbiol       Date:  2010-02-08       Impact factor: 3.501

10.  Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria.

Authors:  Simon J Draper; Anna L Goodman; Sumi Biswas; Emily K Forbes; Anne C Moore; Sarah C Gilbert; Adrian V S Hill
Journal:  Cell Host Microbe       Date:  2009-01-22       Impact factor: 21.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.